Nanotechnology company Liquidia Technologies has a new chief financial officer.
Timothy Albury comes to Research Triangle Park-based Liquidia from Wilmington company Osmotica Pharmaceutical Corp., where he has worked since 2009. Liquidia said that Albury’s tenure at Osmotica included leading a global financial restructuring and and co-leading efforts in M&A as well as international collaborations. That experience could be important to Liquidia, which has reached several development agreements in the United States and around the world involving the company’s proprietary “PRINT” nanoparticle manufacturing technology. One of Liquidia’s most prominent licensing deals was an agreement struck with GlaxoSmithKline last year. GSK is researching ways to use Liquidia’s technology in its vaccine development efforts.
“We are very pleased to welcome someone with Tim’s background and experience to the Liquidia team,” CEO Neal Fowler said in a statement. “Tim’s financial expertise and his demonstrated ability to successfully grow companies will make him a key contributor as Liquidia accelerates its product development capabilities and continues to leverage the PRINT platform to advance more products across different applications.”
